Dementia with Lewy bodies: The principles of diagnostics, treatment, and management

Medicina (Lithuania)

Volumn 48, Issue 1, 2012, Pages 1-8

  Macijauskiene, Jurate ^a   Lesauskaite, Vita ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Dementia syndrome; Dementia with lewy bodies; Diagnostics; Management; Treatment

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT;

BEHAVIOR THERAPY; CAREGIVER; DEMENTIA; EDUCATION; HUMAN; LEWY BODY; METHODOLOGY; REVIEW; SOCIAL SUPPORT;

ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; CAREGIVERS; CHOLINESTERASE INHIBITORS; DEMENTIA; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LEWY BODIES; NEUROPROTECTIVE AGENTS; SOCIAL SUPPORT;

EID: 84863510153     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina48010001     Document Type: Review

References (75)

1. Kosaka K, Oyanagi S, Matsushita M, Hori A, Iwase S. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol 1976;36:221-33.
2. Kosaka K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol 1978;42:127-34.
3. Graeber MB, Mueller U. Dementia with Lewy bodies: disease concept and genetics. Neurogenetics 2003;4:157-62.
4. Ince PG, Perry EK, Morris CM. Dementia with Lewy bodies. A distinct non-Alzheimer dementia syndrome? Brain Pathol 1998;8:299-324.
5. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34:561-6.
6. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol 2007;27(1):42-7.
7. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien IT, Cummings J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-72.
8. Dong M, Peng B, Lin X, Zhao J, Zhou Y, Wang R. The prevalence of dementia in the People's Republic of China: a systematic analysis of 1980-2004 studies. Age Ageing 2007;36(6):619-24.
9. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002;58(2):209-18.
10. Londos E, Passant U, Gustafson L, Brun A. Neuropathological correlates to clinically defined dementia with Lewy bodies. Int J Geriatr Psychiatry 2001;16:667-79.
11. Kövari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull 2009;80:203-10.
12. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
13. Cookson MR. alpha-Synuclein and neuronal cell death. Mol Neurodegener 2009;4:9.
14. Trojanowski JQ, Lee VMY. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 1998;55:151-2
15. Galvin JE, Lee VMY, Trojanowski JQ. Synucleinopathies. Arch Neurol 2001;58:186-90
16. Beyer K, Domingo-Sabat M, Santos C, Tolosa E, Ferrer I, Ariza A. The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies. Brain 2010;133:3724-33.
17. Terada S, Ishizu H, Yokota O, Tsuchiya K, Nakashima H, Ishihara T, et al. Glial involvement in diffuse Lewy body disease. Acta Neuropathol 2003;105:163-9.
18. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
19. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurology 2004;3(1):19-28.
20. Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 2005;20(12):11-20.
21. McKeith IG, Wesnes K, Perry E, Ferrara R. Greater attentional deficits and responses to rivastigmine in dementia with Lewy body patients with visual hallucination. Dement Geriatr Cogn Disord 2004;18:94-100.
22. Reilly J, Rodriguez AD, Lamy M, Neils-Strunjas J. Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview. J Commun Disord 2010;43:438-52.
23. Doubleday EK, Snowden JS, Varma AR, Neary D. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72(5):602-7.
24. Ferman TJ, Smith GE, Boeve BF, Graff-Radford NR, Licas JA, Knopman DS, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol 2006;20(4):623-36.
25. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4(6):428-30.
26. Barber R, Ballard C, McKeith IG, Gholkar A, O'Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000;54(6):1304-9.
27. Shimizu S, Hanyu H, Kanetaka H, Iwamoto T, Koizumi K, Abe K, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using SPECT. Dement Geriatr Cogn Disord 2005;20:25-30.
28. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56:643-9.
29. Miyazawa N, Shinohara T, Nagasaka T, Hayashi M. Hypermetabolism in patients with dementia with Lewy bodies. Clin Nucl Med 2010;35:490-3.
30. Sato T, Hanyu K, Hirao S et al. Deep gray matter hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Eur J Neur 2007;14:1299-1301
31. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007;80:S71-S77.
32. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, et al. Value of I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66:1850-4.
33. Estorch M, Camacho V, Paredes P, Rivera E, Rodriguez-Revuelto A, Flotats A, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008;35:1636-41.
34. Kobayashi S, Tateno M, Morii M, Utsumi K, Saito T. Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies. Psychiatry Research 2009;74:76-80.
35. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007;12:671-80.
36. Schlossmacher MG. Quantification of alpha-synuclein in dopamine cells, peripheral blood, genotyped brain and CSF. Neurodegener Dis 2007;4:187.
37. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010;81:608-10.
38. Briel RC, McKeith IG, Barker WA, Hewitt Y, Perry RH, Ince PG, et al. EEG findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;66:401-3.
39. Kurz MW, Larsen JP, Kvaloy JT, Aarsland D. Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: a communitybased, longitudinal study. Mov Disord 2006;21(12):2170-4.
40. Singleton AB, Wharton A, O'Brien KK, Walker MP, Mc-Keith IG, Ballard CG, et al. Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002;14:167-75.
41. Santpere G, Ferrer I. LRRK2 and neurodegeneration. Acta Neuropathol 2009;117:227-46.
42. Kobayashi S, Tateno M, Park TW, Utsumi K, Sohma H, et al. Apolipoprotein E4 frequencies in a Japanese population with Alzheimer's disease and dementia with Lewy bodies. PLoS ONE 2011;6(4):e18569.
43. Helmes E, Bowler JV, Merskey H, Munoz DG, Hachinski VC. Rates of cognitive decline in Alzheimer's disease and disease with Lewy bodies. Dement Geriatr Cogn Disord 2003;15:67-71.
44. Ferman TJ, Dickson DW, Graff-Radford N. Early onset of visual hallucinations in dementia distinguishes pathologically-confirmed Lewy body disease from AD. Neurology 2003;60(5):A264.
45. Williams MM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 2006;67:1935-41.
46. Fujishiro H, Umegaki H, Suzuki Y, Isojima D, Akatsu H, Ikari H, et al. Clinical profiles of autopsy-confirmed dementia with Lewy bodies at institutionalization: comparison with Alzheimer's disease. Psychogeriatrics 2007;7(3):98-103.
47. Ferman TJ, Boeve BF. Dementia with Lewy bodies. Neurol Clin 2007;25:741-760.
48. Calderon J, Perry RJ, Erzlinclioglu SW, Berrios GE, DEnig TR, Hodges JR. Perception, attention, and working memory are disproportionally impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:157-64.
49. Theuns J, Van Broeckhoven C. Alpha-synuclein gene duplications in sporadic Parkinson disease. Neurology 2008; 70(1):7-9.
50. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-9.
51. Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, et al. Lewy body dementia and Parkinson's disease with dementia. J Neurol 2008;255(5):39-47.
52. Bear MF, Connors BW, Paradiso MA. Neuroscience: exploring the brain. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins Publishers; 2007.
53. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, Mc-Cullough ML, Calle EE, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol 2006;60(2):197-203.
54. Byrne EJ, Lennox G, Lowe J, Godwin-Austen RB. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry 1989;52(6):709-17.
55. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22(12):1689-707.
56. Burns A, O'Brien J. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-75.
57. Simard M, van Reekum R. The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2004;16:409-25.
58. Fujita Y, Takebayashi M. Efficacy of low-dose donepezil for visual hallucinations in a patient with dementia with Lewy bodies. Psychiatry Clin Neurosci 2010;64:336.
59. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356(9247):2031-6.
60. Dalfo E, Albasanz JL, Martin M, Ferrer I. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C(PLCbeta1) interactions. Brain Pathol 2004;14:388-9.
61. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a doubleblind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7):613-8.
62. Emre M, Tsolaki M, Bonucelli U, Destée A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:969-77.
63. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005;76:1200-3.
64. Bonelli SB, Ransmayr G, Steffelbauer M, Lukas T, Lampl C, Deibl M. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004;63(2):376-8.
65. Braga CA, Follmer C, Palhano FL, Khattar E, Freitas MS, Romão L, et al. The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species. J Mol Biol 2011; 405:254-73.
66. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678.
67. Ballard C, Grace I, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998;351:1032-3.
68. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:549-33.
69. Mulsant BH, Gharabawi GM, Bossie CA, Mao L, Martinez RA, Tune LE, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004;65:1708-14.
70. Fischer C, Bozanovic R, Atkins JH, Rourke SB. Treatment of delusions in dementia with Lewy bodies - response to pharmacotherapy. Dement Geriatr Cogn Disord 2007;23: 307-11.
71. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998;10:227-9.
72. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:146-57.
73. Burgut FT, Kellner CH. Electroconvulsive therapy (ECT) for dementia with Lewy bodies. Med Hypotheses 2010;75: 139-40.
74. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A, Zarit SH. Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord 2010;24:177-81.
75. Etters L, Goodall D, Harrison BE. Caregiver burden among dementia patient caregivers: a review of the literature. J Acad Nurse Pract 2008;20:423-8.